Last updated: February 20, 2026
What is NDC 70756-0701?
NDC 70756-0701 designates Ocrevus (ocrelizumab), a monoclonal antibody indicated for multiple sclerosis (MS) — both relapsing forms and primary progressive MS. Since its approval, Ocrevus has targeted a significant segment within MS treatment, with strong market penetration.
Market Overview
Therapeutic Market Context
- Ocrevus competes primarily with other disease-modifying therapies (DMTs) such as Tysabri (natalizumab), Gilenya (fingolimod), Aubagio (teriflunomide), and Kesimpta (ofatumumab).
- Globally, MS treatment access is expanding, with the global MS drug market valued at approximately $22.3 billion in 2022 and expected to grow at a compound annual growth rate (CAGR) of around 6.1% through 2030 [1].
Market Penetration & Adoption
- In the U.S., Ocrevus has captured a leading share among infused MS therapies as of the latest quarter, with sales exceeding $2 billion annually [2].
- Market penetration has been driven by its efficacy in primary progressive MS, where treatment options are limited.
Clinical Adoption Trends
- Physicians favor Ocrevus for its dual indication and dosing schedule (every six months), which improves adherence.
- Insurance coverage remains generally favorable, but post-approval healthcare policies influence access.
Price Positioning & Cost Dynamics
Current Pricing Landscape
| Drug Name |
List Price (per 300 mg vial) |
Administration Cost |
Estimated Annual Cost (U.S.) |
| Ocrevus (70756-0701) |
$7,600 per vial |
$2,000 (administration) |
~$69,000 |
| Tysabri (natalizumab) |
$3,800 per injection |
$1,200 |
~$81,600 |
| Gilenya (fingolimod) |
Oral, ~$7,641 monthly |
— |
~$91,692 |
Note: Ocrevus dosing comprises two 300 mg infusions initially, then 600 mg every six months. Actual costs depend on negotiated discounts and payer arrangements.
Pricing Strategies and Reimbursement
- The price premium for Ocrevus stems from its efficacy in both relapsing-remitting MS and primary progressive MS.
- Payer negotiation strategies are commonplace, often reducing net prices by 15-25%.
- The infusion route amplifies costs related to administration and healthcare facility charges.
Price Projection Analysis
Factors Influencing Price Trajectory
- Patent expiration: No immediate patent expiry scheduled before 2030; generic entrants unlikely soon.
- Market competition: Introduction of biosimilars or new MOA therapies could pressure prices.
- Regulatory shifts: Potential for policy changes in drug pricing, especially in the U.S.
- Manufacturing costs: Stability expected, with no significant cost reductions anticipated without technological breakthroughs.
Short-term (1-3 years)
- Price stability projected within a 0-3% increase annually, driven by inflation, inflation-related administration costs, and standard pricing adjustments.
- Net price reductions of 10-15% likely due to payer discounts and patient assistance programs.
Medium-term (4-7 years)
- Projected price increase of 2-4% annually, reflective of inflation adjustments and increased demand.
- Possible price plateau if biosimilars or competitors acquire approval; but significant price erosion unlikely before patent expiry.
Long-term (8+ years)
- Potential price decline if biosimilars gain market share post-patent expiration; price reductions of 30-50% are plausible.
- Market-driven consolidation may alter pricing structures and negotiation power.
Revenue & Market Share Forecasts
| Year |
Estimated Global Sales (USD billion) |
Projected Market Share |
Key Drivers |
| 2023 |
$2.2 billion |
25% |
Ongoing clinical adoption |
| 2025 |
$2.5 billion |
27% |
Expanding indications and access |
| 2030 |
$3.2 billion |
30% |
Competition intensity plateau |
Note: Assumes consistent market penetration and no disruptive biosimilar entry before patent expiry.
Key Takeaways
- Ocrevus (NDC 70756-0701) maintains a dominant position within MS treatment, with stable pricing expected in the medium term.
- The U.S. price is approximately $69,000/year, with variations based on discounts and payer negotiations.
- Long-term risks include biosimilar competition after patent expiry, which could lead to a 30-50% price decline.
- Market growth will continue due to increased MS prevalence, especially in aging populations and expanding global access.
- Pricing strategies remain heavily influenced by insurance reimbursement policies, clinical efficacy, and competition.
FAQs
Q1: How does the price of Ocrevus compare to similar MS therapies?
A: It is more expensive than self-injectable oral drugs like Gilenya but less costly than some infused therapies like Tysabri, factoring in administration costs and therapy efficacy.
Q2: When might biosimilars for ocrelizumab enter the market?
A: Patent expiration is expected around 2030, but biosimilar approval timelines depend on regulatory processes, with entry likely several years thereafter.
Q3: What factors might lead to price increases for Ocrevus?
A: Healthcare inflation, expanded indications, and increased demand could drive modest annual price increases of 2-4%.
Q4: What is the impact of policy changes on Ocrevus pricing?
A: Policy shifts toward value-based reimbursement or price regulation could limit pricing power or induce discounts.
Q5: How do discounts and rebates influence net revenue?
A: Negotiated discounts typically reduce the net price by 15-25%, significantly impacting revenue projections.
References
[1] Grand View Research. (2022). Multiple Sclerosis Market Size, Share & Trends Analysis Report.
[2] IQVIA. (2022). U.S. Pharma Market Data: MS Treatments.
[3] FDA. (2017). Ocrevus (ocrelizumab) prescribing information.
